The American Society of Clinical Oncology (ASCO) 2017 meeting was so full of fascinating panels, abstracts, and articles, that we are only fully catching up now. We’d like to shine a spotlight on a particular article from the ASCO Daily News printed on Sunday, June 4th (on the ASCO website May 25, 2017): “Expert Editorial: Is There an Optimal Dose of Ipilimumab in Melanoma?” by Dr. Jason J. Luke, MD, FACP, (Assistant Professor of medicine (Melanoma and Developmental Therapeutics Clinics), The University of Chicago).
Discussion of the immunotherapy treatment ipilumumab, or yervoy, has been a hot topic in melanoma discourse since ipilimumab was taken off of the market as a first-line treatment for advanced cases of melanoma. Prior to this, ipilimumab had regulatory approval for the treatment of advanced melanoma; however the trials of a 10 mg/kg dose were deemed to have inadequate safety follow-up, and therefore only the 3 mg/kg dose received approval. The most effective dose of ipilimumab was tested in the phase III CA 184-169 trial, which Dr. Luke outlines in his article. While this trial would suggest that there is no role for solitary ipilimumab in either the 3 mg/kg or 10 mg/kg dose as a first-line treatment in cases of advanced melanoma, Dr. Luke explores the ways in which ipilimumab can still be used in clinical practice and as an investigative tool for future combination therapies.
The full text of the article can be read here.